Study of AMV564 in Patients With AML

NCT03144245 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL: AMV564
COMBINATION_PRODUCT: AMV564 in combination with pembrolizumab

Sponsor

Amphivena Therapeutics, Inc.